Literature DB >> 28144891

The course of anxiety, depression and unmet needs in survivors of diffuse large B cell lymphoma and multiple myeloma in the early survivorship period.

Devesh Oberoi1, Victoria White2,3, John Seymour4,5, H Miles Prince4,5, Simon Harrison4,5, Michael Jefford4,5, Ingrid Winship6, David Hill1,4, Damien Bolton7, Anne Kay8, Jeremy Millar9, Nicole Wong Doo10, Graham Giles1.   

Abstract

PURPOSE: The purpose of the study is to examine the course of anxiety, depression and unmet needs in diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) survivors in the first 2 years post diagnosis.
METHODS: DLBCL and MM survivors, recruited through the Victorian Cancer Registry, completed two interviews approximately 7 and 15 months post diagnosis. Hospital Anxiety and Depression Scale (HADS) and Supportive Care Needs Survey (SCNS-SF34) were completed at both interviews. Primary outcomes were prevalence of anxiety, depression and unmet needs (any or moderate-high). Generalized estimating equation examined whether course of anxiety, depression and unmet needs differed between the two cancers.
RESULTS: Overall, 236 DLBCL and 178 MM survivors completed both telephone interviews. Course of anxiety differed (p < 0.01) with rate increasing in DLBCL (14 to 22%) while remaining stable for MM (15 to 12%). Course of depression also differed (p < 0.01), decreasing for MM (22 to 12%) and remaining stable for DLBCL (15 to 16%) survivors. Change in unmet needs was generally similar for the two cancer groups, except for moderate to high psychological needs (p < 0.05).
CONCLUSIONS: Patterns of change in anxiety and depression in first 2 years post diagnosis differ for DLBCL and MM survivors. IMPLICATIONS FOR CANCER SURVIVORS: Studying psychological outcomes in mixed haematological cancer samples may be inappropriate, at least in the early survivorship phase. Separate studies of the experiences of people with the different haematological cancer subtypes are needed to ensure psychosocial and supportive care interventions are appropriate to the needs of individuals with different haematological cancers.

Entities:  

Keywords:  Cancer survivorship; Diffuse large B cell lymphoma; Haematological cancer; Multiple myeloma; Psychosocial oncology

Mesh:

Year:  2017        PMID: 28144891     DOI: 10.1007/s11764-016-0591-y

Source DB:  PubMed          Journal:  J Cancer Surviv        ISSN: 1932-2259            Impact factor:   4.442


  38 in total

1.  Unmet needs of Australian and Canadian haematological cancer survivors: a cross-sectional international comparative study.

Authors:  Alix Hall; H Sharon Campbell; Rob Sanson-Fisher; Marita Lynagh; Catherine D'Este; Robin Burkhalter; Mariko Carey
Journal:  Psychooncology       Date:  2013-02-25       Impact factor: 3.894

Review 2.  Common complaints, difficult diagnosis: multiple myeloma.

Authors:  Colleen Dvorak
Journal:  J Am Acad Nurse Pract       Date:  2006-05

3.  Assessment of depression and anxiety in haematological cancer patients and their relationship with quality of life.

Authors:  Das Priscilla; Awang Hamidin; M Zain Azhar; Khin Ohnmar Naing Noorjan; M Said Salmiah; Khalid Bahariah
Journal:  East Asian Arch Psychiatry       Date:  2011-09

4.  Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners.

Authors:  Alex Molassiotis; Barbara Wilson; Susan Blair; Tracy Howe; James Cavet
Journal:  Psychooncology       Date:  2011-01       Impact factor: 3.894

5.  The relation between the experience of time and psychological distress in patients with hematological malignancies.

Authors:  Marc Wittmann; Tanja Vollmer; Claudia Schweiger; Wolfgang Hiddemann
Journal:  Palliat Support Care       Date:  2006-12

6.  Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Matthew J Maurer; Hervé Ghesquières; Jean-Philippe Jais; Thomas E Witzig; Corinne Haioun; Carrie A Thompson; Richard Delarue; Ivana N Micallef; Frédéric Peyrade; William R Macon; Thierry Jo Molina; Nicolas Ketterer; Sergei I Syrbu; Olivier Fitoussi; Paul J Kurtin; Cristine Allmer; Emmanuelle Nicolas-Virelizier; Susan L Slager; Thomas M Habermann; Brian K Link; Gilles Salles; Hervé Tilly; James R Cerhan
Journal:  J Clin Oncol       Date:  2014-02-18       Impact factor: 44.544

7.  Patients' supportive care needs beyond the end of cancer treatment: a prospective, longitudinal survey.

Authors:  Jo Armes; Maggie Crowe; Lynne Colbourne; Helen Morgan; Trevor Murrells; Catherine Oakley; Nigel Palmer; Emma Ream; Annie Young; Alison Richardson
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

8.  When the safety net of treatment has been removed: patients' unmet needs at the completion of treatment for haematological malignancies.

Authors:  E A Lobb; D Joske; P Butow; L J Kristjanson; P Cannell; G Cull; B Augustson
Journal:  Patient Educ Couns       Date:  2009-03-09

9.  Caregivers' information needs and their 'experiences of care' during treatment are associated with elevated anxiety and depression: a cross-sectional study of the caregivers of renal cancer survivors.

Authors:  Devesh V Oberoi; Vicki White; Michael Jefford; Graham G Giles; Damien Bolton; Ian Davis; Ingrid Winship; H Miles Prince; Jeremy Millar; Simon Harrison; Anne Kay; David Hill
Journal:  Support Care Cancer       Date:  2016-05-05       Impact factor: 3.603

10.  Course of distress, anxiety, and depression in hematological cancer patients: Association between gender and grade of neoplasm.

Authors:  Cristiane Decat Bergerot; Karen Lynn Clark; Alexandre Nonino; Sarah Waliany; Marco Murilo Buso; Matthew Loscalzo
Journal:  Palliat Support Care       Date:  2013-11-04
View more
  7 in total

1.  Factors influencing supportive care needs of multiple myeloma patients treated with chemotherapy.

Authors:  Yoo-Rin Cho; Yang-Sook Yoo
Journal:  Support Care Cancer       Date:  2019-07-18       Impact factor: 3.603

Review 2.  Unmet Supportive Care Needs of Patients with Hematological Malignancies: A Systematic Review.

Authors:  Ioanna Tsatsou; Theocharis Konstantinidis; Ioannis Kalemikerakis; Theodoula Adamakidou; Eugenia Vlachou; Ourania Govina
Journal:  Asia Pac J Oncol Nurs       Date:  2020-10-15

3.  Disability, psychological distress and quality of life in relation to cancer diagnosis and cancer type: population-based Australian study of 22,505 cancer survivors and 244,000 people without cancer.

Authors:  Grace Joshy; Joanne Thandrayen; Bogda Koczwara; Phyllis Butow; Rebekah Laidsaar-Powell; Nicole Rankin; Karen Canfell; John Stubbs; Paul Grogan; Louise Bailey; Amelia Yazidjoglou; Emily Banks
Journal:  BMC Med       Date:  2020-12-01       Impact factor: 8.775

4.  Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study.

Authors:  Alexandra-Cristina Paunescu; Christiane Bergman Copie; Sandra Malak; Steven Le Gouill; Vincent Ribrag; Krimo Bouabdallah; David Sibon; Gerhard Rumpold; Marie Preau; Nicolas Mounier; Corinne Haioun; Fabrice Jardin; Caroline Besson
Journal:  Ann Hematol       Date:  2021-10-06       Impact factor: 3.673

5.  Living with or beyond lymphoma: A rapid review of the unmet needs of lymphoma survivors.

Authors:  Vanessa Boland; Amanda Drury; Greg Sheaf; Anne-Marie Brady
Journal:  Psychooncology       Date:  2022-06-27       Impact factor: 3.955

6.  Test-Retest Reliability of the Short-Form Survivor Unmet Needs Survey.

Authors:  Karen Taylor; Max Bulsara; Leanne Monterosso
Journal:  Asia Pac J Oncol Nurs       Date:  2018 Apr-Jun

7.  Shared care follow-up of patients with B-cell neoplasms based on nurse-led telephone consultations and PRO-data: a feasibility study from the North Denmark Region.

Authors:  Mia Sommer; Lone Frandsen; Paw Jensen; Søren Ramme Nielsen; Lars Børty Nielsen; Rasmus Froberg Brøndum; Martin Bøgsted; Jakob Madsen; Marianne Tang Severinsen; Erik Elgaard Sørensen; Mette Grønkjær; Tarec Christoffer El-Galaly
Journal:  BMC Health Serv Res       Date:  2020-11-17       Impact factor: 2.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.